The news this week that a GLP-1 agonist had succeeded in improving the symptoms of Parkinson’s disease was curious for two reasons: one, several trials of similar incretins in the condition have failed; and two, the trial was conducted by academic researchers rather than a pharma company.
Key Takeaways
- Lixisenatide, a GLP-1 agonist, has shown potential in treating Parkinson’s disease
- Prior trials of similar drugs have failed
- But several other incretins, including semaglutide, are in active
The molecule in question is lixisenatide, better known as Sanofi’s diabetes medicine Adlyxin